Pregled bibliografske jedinice broj: 93747
A randomized, double blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species
A randomized, double blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species // British Journal of Dermatology, 146 (2002), 816-823 (podatak o recenziji nije dostupan, prikaz, znanstveni)
CROSBI ID: 93747 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
A randomized, double blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species
Autori
Lipozenčić, Jasna ; Skerlev, Mihael, Orofino-Costa, R, Zaitz, V, C ; Horvath, A ; Chouela, E ; Romero, G ; Gourmala, N ; Paul, C ; and The Tinea Capitis Study Group
Izvornik
British Journal of Dermatology 146
(2002);
816-823
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, prikaz, znanstveni
Ključne riječi
Microsporum species; terbinafine; tinea capitis
Sažetak
Tinea capitis, a common clinical pattern of dermatophyte infection in children is bedoming a public health hazard in some countries. Several studie have reported terbinafine to be a save and well tolerated fungicidal drug for the treatment of this infection. However, the optimal treatment duration for each use in the treatment of tinea capitis caused by Microsporum species has not yet been determined.To establish the optimal duration for terbinafine treatment to bring about complete cure of tinea capitis due to Microsporum infection in a large paediatric population, and (ii) to obtain information of the maximum therapeutic effect of the existing therapy. This parallel group doubl.eblind, multucentre study was coducted in Europe and South America. In goup of 134 intention-to-treat patients, effective treatment was observed at the end of study in 62%patients treated with terbinafine for 6 weeks and in 63% treated for 8 weeks. Complete cure was observed at the of study in 62 patients treated with terbinafine for 6 weeks, in 60% treated for 8 weeks and in 84% patients treated with griseofulvin for 12 weeks. Terbinafine therarapy for 6 weeks could represent and alternative to griseofulvin for the treatment of Microsporum tineac capitis. However, further clinical trials are required in order to optimize the dose regimen to allow higher cure rates to be reached.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- SCI-EXP, SSCI i/ili A&HCI
Uključenost u ostale bibliografske baze podataka::
- Biological Abstracts